Literature DB >> 8549275

Quo vadis with bacterial resistance?

J D Williams1.   

Abstract

Mesh:

Year:  1995        PMID: 8549275     DOI: 10.2165/00003495-199500492-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  7 in total

1.  Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.

Authors:  J M Diver; T Schollaardt; H R Rabin; C Thorson; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

2.  Emergence of multiply resistant pneumococci.

Authors:  M R Jacobs; H J Koornhof; R M Robins-Browne; C M Stevenson; Z A Vermaak; I Freiman; G B Miller; M A Witcomb; M Isaäcson; J I Ward; R Austrian
Journal:  N Engl J Med       Date:  1978-10-05       Impact factor: 91.245

3.  Pneumococci insensitive to penicillin.

Authors:  D Hansman; H N Glasgow; J Sturt; L Devitt; R M Douglas
Journal:  Nature       Date:  1971-04-09       Impact factor: 49.962

4.  The treatment of bacteriuria in pregnant women with sulphamethoxazole and thrimethoprim. A microbiological, clinical and toxicological study.

Authors:  J D Williams; W Brumfitt; A P Condie; D S Reeves
Journal:  Postgrad Med J       Date:  1969-11       Impact factor: 2.401

5.  Pseudomonas aeruginosa isolates with modified beta-lactamase inducibility: effects on beta-lactam sensitivity.

Authors:  D M Livermore; R J Williams; M A Lindridge; R C Slack; J D Williams
Journal:  Lancet       Date:  1982-06-26       Impact factor: 79.321

6.  Frequency of appearance of resistant variants to norfloxacin and nalidixic acid.

Authors:  G J Duckworth; J D Williams
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

Review 7.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

  7 in total
  1 in total

1.  A reappraisal of quinolone tolerability. The experience of their musculoskeletal adverse effects.

Authors:  G Hayem; C Carbon
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.